Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

trametinib 4nilotinib 4elotuzumab 4dabrafenib 4Amifampridine 4regorafenib 3pembrolizumab 3midostaurin 3fludarabine phosphate 3fludarabine 3Nivolumab 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Cyclophosphamide 3Crizotinib 3Bortezomib 3Axitinib 3venetoclax 2veliparib 2tazemetostat 2talimogene laherparepvec 2navitoclax 2gallium 68 PSMA-11 2ceritinib 2carbon-11 acetate 2aldesleukin 2Whole-Body Irradiation 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × Expanded_access × derazantinib × Clear all
NCT04087876 2025-04-06

Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

Basilea Pharmaceutica

No longer available
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Liver Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡